LIVE on April 23rd: Has Covid impacted India's long-term growth potential?
Here is the latest financial fact sheet of Biocon. For more details, see the Biocon quarterly results and Biocon share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | -1.3 |
No. of shares | m | 600.00 |
% ch week | % | -0.7 |
% ch 1-mth | % | 1.3 |
% ch 12-mth | % | 12.1 |
52 week H/L | Rs | 487.7/320.9 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
BIOCON EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 554 | 496 | 1,162 | 1,188 | 707 | |
Low | Rs | 407 | 397 | 483 | 305 | 554 | |
Sales per share (Unadj.) | Rs | 154.5 | 167.4 | 194.6 | 68.7 | 91.9 | |
Earnings per share (Unadj.) | Rs | 24.9 | 30.5 | 34.4 | 7.6 | 16.7 | |
Diluted earnings per share | Rs | 8.3 | 10.2 | 11.5 | 7.6 | 16.7 | |
Cash flow per share (Unadj.) | Rs | 35.9 | 42.9 | 48.3 | 14.0 | 24.2 | |
Dividends per share (Unadj.) | Rs | 5.00 | 5.00 | 1.00 | 1.00 | 1.00 | |
Adj. dividends per share | Rs | 1.67 | 1.67 | 0.33 | 1.00 | 1.00 | |
Dividend yield (eoy) | % | 1.0 | 1.1 | 0.1 | 0.1 | 0.2 | |
Book value per share (Unadj.) | Rs | 163.1 | 201.7 | 241.9 | 86.3 | 101.6 | |
Adj. book value per share | Rs | 54.4 | 67.2 | 80.6 | 86.3 | 101.6 | |
Shares outstanding (eoy) | m | 200.00 | 200.00 | 200.00 | 600.00 | 600.00 | |
Bonus/Rights/Conversions | - | - | - | IS | - | ||
Price / Sales ratio | x | 3.1 | 2.7 | 4.2 | 10.9 | 6.9 | |
Avg P/E ratio | x | 19.3 | 14.6 | 23.9 | 98.9 | 37.7 | |
P/CF ratio (eoy) | x | 13.4 | 10.4 | 17.0 | 53.4 | 26.1 | |
Price / Book Value ratio | x | 2.9 | 2.2 | 3.4 | 8.6 | 6.2 | |
Dividend payout | % | 20.1 | 16.4 | 2.9 | 13.2 | 6.0 | |
Avg Mkt Cap | Rs m | 96,080 | 89,220 | 164,440 | 447,900 | 378,330 | |
No. of employees | `000 | 7.5 | 4.4 | 9.2 | 6.1 | 6.1 | |
Total wages/salary | Rs m | 5,334 | 6,101 | 7,470 | 9,311 | 11,653 | |
Avg. sales/employee | Rs Th | 4,119.7 | 7,581.9 | 4,213.9 | 6,705.8 | 8,994.3 | |
Avg. wages/employee | Rs Th | 711.2 | 1,381.9 | 809.0 | 1,514.2 | 1,900.7 | |
Avg. net profit/employee | Rs Th | 663.2 | 1,379.6 | 745.2 | 736.9 | 1,635.3 |
BIOCON INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 30,898 | 33,474 | 38,911 | 41,234 | 55,144 | |
Other income | Rs m | 531 | 792 | 1,571 | 2,062 | 1,444 | |
Total revenues | Rs m | 31,429 | 34,266 | 40,482 | 43,296 | 56,588 | |
Gross profit | Rs m | 6,958 | 7,678 | 9,795 | 8,291 | 15,883 | |
Depreciation | Rs m | 2,210 | 2,487 | 2,772 | 3,851 | 4,478 | |
Interest | Rs m | 89 | 293 | 260 | 615 | 709 | |
Profit before tax | Rs m | 5,190 | 5,690 | 8,334 | 5,887 | 12,140 | |
Minority Interest | Rs m | -310 | 217 | 163 | 213 | 9 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 1,051 | 1,606 | 0 | 0 | 0 | |
Tax | Rs m | 957 | 1,422 | 1,616 | 1,569 | 2,123 | |
Profit after tax | Rs m | 4,974 | 6,091 | 6,881 | 4,531 | 10,026 | |
Gross profit margin | % | 22.5 | 22.9 | 25.2 | 20.1 | 28.8 | |
Effective tax rate | % | 18.4 | 25.0 | 19.4 | 26.7 | 17.5 | |
Net profit margin | % | 16.1 | 18.2 | 17.7 | 11.0 | 18.2 |
BIOCON BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 24,750 | 39,709 | 40,477 | 41,486 | 48,228 | |
Current liabilities | Rs m | 15,974 | 16,657 | 16,783 | 21,413 | 30,376 | |
Net working cap to sales | % | 28.4 | 68.9 | 60.9 | 48.7 | 32.4 | |
Current ratio | x | 1.5 | 2.4 | 2.4 | 1.9 | 1.6 | |
Inventory Days | Days | 56 | 59 | 60 | 64 | 68 | |
Debtors Days | Days | 81 | 78 | 83 | 94 | 86 | |
Net fixed assets | Rs m | 34,169 | 40,146 | 45,073 | 50,661 | 64,130 | |
Share capital | Rs m | 1,000 | 1,000 | 1,000 | 3,000 | 3,000 | |
"Free" reserves | Rs m | 31,622 | 39,338 | 47,377 | 48,808 | 57,980 | |
Net worth | Rs m | 32,622 | 40,338 | 48,377 | 51,808 | 60,980 | |
Long term debt | Rs m | 7,671 | 20,724 | 21,082 | 18,083 | 15,766 | |
Total assets | Rs m | 63,319 | 84,581 | 93,942 | 99,897 | 121,924 | |
Interest coverage | x | 59.3 | 20.4 | 33.1 | 10.6 | 18.1 | |
Debt to equity ratio | x | 0.2 | 0.5 | 0.4 | 0.3 | 0.3 | |
Sales to assets ratio | x | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | |
Return on assets | % | 8.0 | 7.5 | 7.6 | 5.2 | 8.8 | |
Return on equity | % | 15.2 | 15.1 | 14.2 | 8.7 | 16.4 | |
Return on capital | % | 14.9 | 12.8 | 12.6 | 9.6 | 16.8 | |
Exports to sales | % | 33.5 | 32.0 | 33.4 | 29.2 | 28.1 | |
Imports to sales | % | 19.7 | 21.2 | 20.3 | 17.8 | 18.9 | |
Exports (fob) | Rs m | 10,339 | 10,717 | 12,988 | 12,058 | 15,506 | |
Imports (cif) | Rs m | 6,102 | 7,105 | 7,899 | 7,348 | 10,399 | |
Fx inflow | Rs m | 10,993 | 11,789 | 12,988 | 12,058 | 15,506 | |
Fx outflow | Rs m | 7,371 | 8,445 | 7,899 | 7,348 | 10,399 | |
Net fx | Rs m | 3,622 | 3,344 | 5,089 | 4,710 | 5,107 |
BIOCON CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 2,107 | 3,706 | 6,400 | 6,621 | 11,546 | |
From Investments | Rs m | -5,087 | -11,417 | -4,985 | -6,840 | -7,138 | |
From Financial Activity | Rs m | 1,862 | 10,676 | -1,775 | -2,397 | -2,417 | |
Net Cashflow | Rs m | -1,118 | 3,000 | -473 | -2,612 | 2,103 |
Share Holding
|
Company Information
|
CHM: Kiran Mazumdar Shaw (MD) | COMP SEC: Kiran Kumar | YEAR OF INC: 1978 | BSE CODE: 532523 | FV (Rs): 5 | DIV YIELD (%): 0.2 |
More Pharmaceuticals Company Fact Sheets: SUVEN LIFE SCIENCES PROCTER & GAMBLE HEALTH JUBILANT PHARMOVA VENUS REMEDIES PIRAMAL ENTERPRISES
Compare BIOCON With: SUVEN LIFE SCIENCES PROCTER & GAMBLE HEALTH JUBILANT PHARMOVA VENUS REMEDIES PIRAMAL ENTERPRISES
Compare BIOCON With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video I tell you the three Nifty ETFs I think are the best.
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More